Skip to content

Homoeopathy for Drug-deaddiction

Efficacy of Individualized Homoeopathy as an adjuvant to standard care in Cannabis and/or Opioid withdrawal syndrome and relapse assessment: A Double blind, Randomized, Placebo Controlled Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/059913
Enrollment
260
Registered
2023-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H- Substance Abuse Treatment

Interventions

Intervention1: Standard care with Individualized Homoeopathic medicine : Homoeopathic Medicines in compliance with pharmacopoeial standards from GMP compliant manufacturers would only be used. The med

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed patients of mild and moderate cannabis and/or opioid use disorder as per DSM V criteria. Patients having intact mental health capacity (as per section 4, Mental healthcare act, 2017) and are willing to quit.

Exclusion criteria

Exclusion criteria: Patients having severe cannabis and/or opioid withdrawals symptoms Patients with history of multiple relapses Patients with other substance dependency like, alcohol, cocaine, amphetamine type stimulants, sedatives, and inhalants .except nicotine Patients with pre-diagnosed co-morbid psychiatric illness like schizophrenia, bipolar depression. Patients presenting with medical emergencies such as intoxication, poisoning, hypertensive encephalopathy, hyperkalemia, severe dehydration. Pre-diagnosed cases of low glomerular filtration rate, raised total serum bilirubin levels, malignancies. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Change in symptomatology to be assessed with the help of Cannabis Withdrawal Scale & Clinical Opiate Withdrawal ScaleTimepoint: Patient will be examined on daily basis for first 7 days & at the end of 2nd, 3rd, and 4th week

Secondary

MeasureTime frame
1. Period of abstinence & relapse if any, with the help of multi-drug urine screen test 2. Change in quality of life to be assessed by WHOQOL BREFTimepoint: 1. At baseline, thereafter at the end of every month after initiation of treatment 2. At baseline, thereafter at the end of 1st month & 6th month

Countries

India

Contacts

Public ContactDr Divya Taneja

Central Council for Research in Homoeopathy

renumittal73@ccrhindia.nic.in9717511115

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026